Stock Price Updates, Growth Prospects, and New Obesity Treatment Guidelines - Research Report on Alexion, HCA, Novartis, LabCorp, and VIVUS

Editor Note: For more information about this release, please scroll to bottom

News provided by

Nov 28, 2013, 08:00 ET

NEW YORK, November 28, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), HCA Holdings, Inc. (NYSE: HCA), Novartis AG (NYSE: NVS), Laboratory Corp. of America Holdings (NYSE: LH), and VIVUS Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report

On November 25, 2013, Alexion Pharmaceuticals, Inc.'s (Alexion) stock declined 0.50%, ending the day at $122.17. Over the previous three trading sessions, shares of Alexion increased 2.61% compared to the Nasdaq Composite, which advanced 1.87% during the same period. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4619_ALXN

HCA Holdings, Inc. Research Report

On November 25, 2013, HCA Holdings, Inc.'s (HCA) stock declined 0.92%, ending the day at $44.35. Over the previous three trading sessions, shares of HCA gained 0.34% compared to the Dow Jones Industrial Average which increased 1.08% during the same period. The Full Research Report on HCA Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/be59_HCA

Novartis AG Research Report

On November 22, 2013, Novartis AG (Novartis) reported a set of key developments in the Company. The Company announced the launch of a $5 billion share buyback, which will commence immediately, and executed over two years on the 2^nd trading line. The Company also stated that it recently announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for $1.7 billion. Novartis further reconfirmed its optimal capital structure with a target rating of double-A. Novartis stated that its pharmaceuticals division is entering a new growth phase, propelled by productive R&D engine. Novartis added that it is developing business segments in Dermatology, Heart Failure, Respiratory and Cell Therapy to complement its Oncology business. The Company informed that it is on track to grow every year in the next five years despite loss of exclusivity for Glivec. Novartis also revealed that Alcon is positioned to deliver above-market growth in the mid to high-single digits in constant currencies, due to its innovative products addressing significant patient need. Joseph Jimenez, CEO of Novartis, commented, "Novartis has reached an inflection point, having fully integrated Alcon and reduced debt. We are now further sharpening the execution of our strategy to strengthen shareholder value through science-based innovation in high-growth segments of healthcare where we have the global scale, competitive advantage and the right capabilities to win." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9b6d_NVS

Laboratory Corp. of America Holdings Research Report

On November 25, 2013, Laboratory Corp. of America Holdings' (LabCorp) stock increased 0.65%, ending the day at $105.84. Over the previous three trading sessions, shares of LabCorp advanced 1.62% compared to the Dow Jones Industrial Average which gained 1.08% during the same period. The Full Research Report on Laboratory Corp. of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c267_LH

VIVUS Inc. Research Report

On November 21, 2013, VIVUS Inc. (VIVUS) announced its support of new clinical practice guidelines encouraging healthcare providers to take on a more active role in an effort to help overweight or obese patients achieve and maintain a healthy body weight. The Company stated that according to the guidelines, obesity medication can be considered as an adjunct to lifestyle intervention to help appropriate patients (individuals with BMI > 30 or BMI > 27 with at least one obesity-associated comorbid condition) achieve their weight loss goals. VIVUS stated that the new guidelines were developed by the American Heart Association, American College of Cardiology and The Obesity Society, along with the National Heart, Lung and Blood Institute.

Barbara Troupin, MD, Vice President, Scientific Communication and Risk Management, VIVUS, commented, "Obesity is a complex condition affecting millions of Americans, and diet and exercise alone are often not enough. VIVUS supports this new guidance, and encourages physicians to work closely with patients to find the treatment plans that will help them achieve the benefits of a lower, healthier weight." The Full Research Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8ae9_VVUS

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner